Population Bio, Inc. a Precision Medicine Company news

Pioneering technology platform rapidly uncovers the genetic causes of unsolved diseases and redefines the understanding of rare and complex genetic diseases.

Melville, NY, (February 28, 2017) Population Bio (PB) – a global leader in gene discovery announced, in support of World Rare Disease Day, its continued investment in its CNV Beacon® gene discovery platform which delivers new knowledge about rare diseases.

The CNV Beacon® platform can discer

Melville, NY, (December 21, 2016) Population Diagnostics – a global leader in gene discovery for complex disease announced today that it is changing its corporate name to Population Bio.  The name change reflects the company`s broader commitment to precision medicine and its expertise in driving the innovations needed to shape the future of drug development and predictive diagnostics.  The new name is effective immediately.

"The new name, Populati

Collaborative Effort to Further Validate Genetic Variants

SUNNYVALE, Calif. and MELVILLE, N.Y., Nov. 20, 2013 /PRNewswire-USNewswire/ -- The Parkinson`s Institute and Clinical Center announced today that they, in partnership with Population Diagnostics, Inc., have discovered a number of new genes relevant to the cause of Parkinson`s disease.

The innovative approach used for this study focuses first on genome-wide investigation of gene copy number variants (CNV

Peer-Reviewed Findings Provide Medically Relevant Content for Early Detection Pre-symptomatic Diagnostics for Autism as well as New Insights into Drug Discovery

Study Demonstrates Potential of Population Diagnostics` Gene Discovery Platform

MELVILLE, NY— (Business Wire 12/10/2012) Population Diagnostics, Inc. ("PDx"), a private company with a novel approach for systematically uncovering the genetic causes of disease